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TO THE EDITOR
Kaposi sarcoma herpesvirus (KSHV) is a
newly identified human herpesvirus
(Chang et al., 1994) and the primary
etiologic agent of Kaposi’s sarcoma
(Gallo, 1998). The entry of KSHV into
cells is a well-orchestrated event yet to
be understood in its entirety. The most
common mucosal site where infectious
KSHV particles have been detected is
the oropharynx, where viable viral par-
ticles are shed into the saliva (Webster-
Cyriaque et al., 2006), which appears
to be a possible source of virus for new
infections (Plancoulaine et al., 2000)
with saliva-borne virions demonstrated
to be infectious (Pauk et al., 2000).
Saliva is a dilute aqueous solution that
lubricates and protects the oral cavity
and provides nonimmune defense
against pathogens (Wu et al., 1994).
Indeed, a high KSHV load was mea-
sured in the oral compartment, which
appeared to be independent from KSHV
titers in the peripheral blood mono-
nuclear cells (Marcelin et al., 2004).
Previously, we demonstrated KSHV to
specifically interact with human lacto-
ferrin (hLf) from saliva, and more
particularly with a non-glycosylated
8-kDa-derived peptide (Grange et al.,
2005). However, the possible role of
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Figure 1. Human lactoferrin (hLf) enhances Kaposi sarcoma herpesvirus (KSHV) infection. Target cells
were incubated for 1 hour at 37 1C with various concentrations of hLf and infected at a multiplicity of
infection (MOI) of 1 ORF73 units of rKSHV.152. (a) Total number of green fluorescent protein (GFP)-
positive cells indicative of infection in each well was counted under a fluorescent microscope at 72 hours
post infection (hPI), and (b) at 3 hPI, internalized KSHV particles were calculated from the corresponding
copy numbers of ORF50 gene determined by quantitative PCR (qPCR). The actual copy numbers of
ORF50 gene detected in hLf-untreated 293 and primary human foreskin fibroblast (HFF) cells were
375±50 and 95±10, respectively. These numbers were considered as 1-fold. Data represent the average
±SD of three independent experiments. Columns with different letters (a–f) are statistically significant
(Po0.05) by least significant difference (LSD).
Abbreviations: GFP, green fluorescent protein; HFF, primary human foreskin fibroblast; hLf, human
lactoferrin; hPI, hours post infection; KSHV, Kaposi sarcoma herpesvirus; qPCR, quantitative PCR
www.jidonline.org 1733
PA Grange et al.
Inhibition of KSHV Infection
hLf in the infectious process of KSHV
has not been addressed until now. On
the basis of our studies, we hypothesize
that hLf binding to KSHV can poten-
tially aid in establishing flexible bridges
between the virus and the target
cells, contributing to the spread of the
disease.
In this study, we analyzed the ability
of hLf and the LF8a/8b-derived peptide
to alter KSHV infection of epithelial
cells (293 cell line) and fibroblasts
(primary human foreskin fibroblast, HFF)
using the recombinant green fluores-
cent protein (GFP) encoding KSHV
(rKSHV.152) (Vieira et al., 2001; see
Supplementary Methods online). Incu-
bating target cells (priming) with var-
ious concentrations of hLf before
infection, significantly enhance, in a
dose-dependent manner, infection of
both 293 and HFF cells. Under hLf-
untreated conditions, we observed
270±33 and 50±10 KSHV-infected
GFP-positive 293 and HFF cells, re-
spectively (Figure 1a). However, the
effect of hLf on KSHV infection of HFF
cells was significantly greater compared
with that in 293 cells (Figure 1). This
could be because of the fact that
inherently 293 cells are more permis-
sive to KSHV infection than HFF cells.
Priming target cells with BSA or a
solution containing 0.05 M sodium acet-
ate and 0.15 M NaCl (vehicle for hLf)
did not alter KSHV infection of cells
(data not shown). These results were
authenticated by performing real-time
DNA PCR (quantitative PCR, qPCR) to
monitor the manner by which hLf
altered the internalization of KSHV
during early stages of infection. Briefly,
cells were primed with various concen-
trations of hLf for 1 hour before infect-
ing cells with rKSHV.152. At the end of
3 hours post infection (hPI), cells were
lysed, total cellular DNA extracted, and
qPCR performed. The copy numbers of
internalized ORF50 (Figure 1b) and
ORF8 (see Supplementary Materials
online, Supplementary Figure S1 on-
line) genes as determined by qPCR
confirmed the ability of hLf to enhance
internalization of KSHV in both 293
and HFF cells (Figure 1b) compared
with BSA (data not shown).
To appreciate the specificity of the
effect of hLf on KSHV infection, we
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Figure 2. Recombinant LF8a/8b inhibit Kaposi sarcoma herpesvirus (KSHV) infection. Purified LF8a/8b
was stained by (a) Coomassie blue, (b) incubated with biotinylated KSHV, or (c) different concentrations
of biotinylated KSHV titrated against the immobilized LF8a/8b. (d) Cells primed with 10 ng ml1 of
human lactoferrin (hLf) were infected with rKSHV.152 that was already pretreated for 1 hour at 37 1C with
Lf8a/8b. Infection was monitored at 72 hPI. KSHV infection of cells in the absence of LF8a/8b was
considered as 100%. (e) Cells primed with hLf were infected with rKSHV.152 pretreated with 10 ng ml1
of LF8a/8b peptide. Internalized KSHV was calculated by quantitative PCR (qPCR). Data represent
the average±SD of three experiments. Asterisks (compared with data points on those treated
with His control) and columns with different letters (a–c) are statistically significant (Po0.05) by
least significant difference (LSD). HFF, primary human foreskin fibroblast; Ni-NTA, nickel-nitrilotriacetic
acid.
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tested the effect of LF8a/8b recombi-
nant peptide on hLf-enhanced KSHV
infection of cells. LF8a/8b peptide cor-
responds to the C-terminal domain of
hLf with which KSHV interacts (Grange
et al., 2005). Subsequently, the gene
encoding the 8-kDa hLf-derived pep-
tide was cloned in an expression vector
showing 77.5% homology with the hLf
sequence (see Supplementary Materials
online, Supplementary Figure S2 on-
line). Recombinant 24-kDa fusion pep-
tide expressed in E. coli BL21 Star was
purified 490% by chromatography
(Figure 2a) and was still recognized by
whole purified biotinylated KSHV par-
ticles (Figure 2b) in a dose-dependent
manner, whereas the His-tagged con-
trol, expressed and purified under the
same conditions, and used as a negative
control, was not (Figure 2c). After gradu-
ally removing urea from the purified
preparation, the LF8a/8b peptide was
tested for its capacity to alter the KSHV
infection of target cells. LF8a/8b pep-
tide significantly neutralized the ability
of hLf to enhance rKSHV.152 infection
as monitored by counting the number
of cells expressing GFP (Figure 2d). We
observed a dose-dependent drop in the
ability of hLf to enhance the KSHV
infection in the presence of LF8a/8b
peptide compared with the His-tagged
control. These results were authenticated
by performing qPCR to quantitate the
effect of LF8a/8b peptide on rKSHV.152
infection of hLf-primed target cells.
Incubating KSHV with 10 ng ml1 of
LF8a/8b peptide before infecting hLf-
primed cells significantly neutralized
hLf-enhanced internalization of KSHV
(Figure 2e). Incubating KSHV with His-
tagged control did not alter hLf-en-
hanced KSHV infection of cells at the
concentrations tested (Figure 2e). The
results indicate LF8a/8b peptide speci-
fically bind KSHV and competitively
block the ability of hLf to enhance
KSHV infection of cells. To our knowl-
edge, these are previously unreported
results, describing the ability of KSHV
to bind to the C-terminal domain of hLf,
which in turn enhances viral infection
of cells. In general, lactoferrin has an
important role as a primary nonspecific
antiviral defense mechanism by pre-
venting viruses from docking to the surface
of target cells as previously described
for herpes simplex virus (Marchetti et al.,
2004), hepatitis B virus (Li et al., 2009),
BK virus (Longhi et al., 2006), and HIV
(Groot et al., 2005). Knowledge con-
cerning hLf as a previously unreported
ligand for KSHV will help us under-
stand the biology of KSHV, with special
emphasis on the entry process and
the possible role of hLf in the KSHV
transmission. These findings also raise
the health disparity question aimed at
understanding the biology of the differ-
ences in the severity of KSHV patho-
genesis among different races: do
people of a particular race express
elevated levels of hLf in their saliva
compared with others? Work along
those lines is already under investiga-
tion by us. Such knowledge on the
peptide derived from salivary hLf
could be used in developing new age
antiviral therapies based on the ability
of the peptide to successfully bind
KSHV and thus neutralize infection.
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